Thermoluminescent chip detector for in vivo dosimetry in pelvis and head & neck cancer treatment.
Our aim is to show the TL dosimetry as a confident QA method for radiotherapy treatments. Before in vivo entrance dose measurements using TLD-100 chips, ECLIPSE TPS-simulated treatments for a Rando anthropomorphic phantom, two for pelvis and one head & neck. In Vivo measurements results with (60)Co beam remained within +/-5% limits. Results for 6 and 15 MV are in conclusion. This is a National Cancer Institute/RJ/Brazil study under the 13.111-IAEA Coordinated Research Project.
Leal
Marcela A
MA
Nuclear Instrumentation Laboratory-COPPE/UFRJ, Rio de Janeiro, Brazil. marcelaleal@lin.ufrj.br
Viegas
Claudio
C
Viamonte
Alfredo
A
Campos
Anna
A
Braz
Delson
D
Clivland
Paul
P
D004867:Equipment Design; D019544:Equipment Failure Analysis; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D010386:Pelvic Neoplasms / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000295:instrumentation*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013819:Thermoluminescent Dosimetry / Q000295:instrumentation*; D014159:Transducers